Editorial: selecting therapy for ulcerative colitis—think a step ahead

The therapeutic armamentarium for patients with active ulcerative colitis (UC) has dramatically increased recently. Several drugs en-compassing six different mechanisms of action (anti- tumour necrosis factor (TNF) agents, anti- adhesion molecules, anti- interleukins (IL) targeting IL- 12 and/or IL- 23, Janus kinase inhibitors and sphingosine-1- phosphate modulators) are already available or will be launched soon. Therefore, selecting the right drug for the right patient at the right time has become more complicated than ever